Want to see HK:2315 full AI Analyst Report?
Top Page
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
(2315)
Select Model
Select Model
Rating:66Neutral
Price Target:
HK$69.00
▲(140.42% Upside)
Action:Reiterated
Date:08/18/26
The score is driven primarily by improved financial performance (profitability and cash flow turning positive, better leverage) and supportive technical momentum with the stock above major moving averages. These positives are materially offset by valuation risk, with a very high P/E indicating elevated expectations.
Positive Factors
Revenue Scale and Margins
Revenue has scaled substantially while gross margins remained high, indicating strong economics and operating scalability across preclinical services, antibody discovery platforms and antibody-asset monetization.
Negative Factors
Free Cash Flow Volatility
Although cash generation improved, the recent decline and history of substantial outflows show that conversion is not yet consistently durable. Renewed R&D spending or weaker operations could pressure funding capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scale and Margins
Revenue has scaled substantially while gross margins remained high, indicating strong economics and operating scalability across preclinical services, antibody discovery platforms and antibody-asset monetization.
Read all positive factors
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$25.82B
Dividend YieldN/A
Average Volume (3M)2.14M
Price to Earnings (P/E)56.4
Beta (1Y)1.13
Revenue Growth48.04%
EPS Growth166.72%
CountryHK
Employees1,443
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.85
Shares Outstanding110,781,920
10 Day Avg. Volume1,999,392
30 Day Avg. Volume2,136,209
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)5.83
Price to Sales (P/S)9.20
P/FCF Ratio44.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.81
Revenue Forecast (FY)HK$1.94B
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments...
How the Company Makes Money
The company primarily makes money by providing technology- and research-based services and by monetizing antibody assets. Key revenue streams include: (1) service income from preclinical R&D and antibody discovery activities enabled by its proprie...
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
70
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.70B | 1.38B | 980.45M | 716.91M | 533.88M | 354.56M |
| Gross Profit | 1.31B | 1.05B | 761.52M | 506.03M | 391.75M | 247.44M |
| EBITDA | 585.05M | 419.49M | 303.80M | -97.87M | -465.86M | -378.12M |
| Net Income | 362.97M | 173.20M | 33.54M | -382.95M | -602.16M | -545.58M |
Balance Sheet | ||||||
| Total Assets | 3.64B | 3.72B | 2.42B | 2.45B | 2.80B | 2.30B |
| Cash, Cash Equivalents and Short-Term Investments | 1.04B | 1.56B | 381.18M | 408.09M | 611.27M | 566.45M |
| Total Debt | 869.00M | 584.09M | 570.28M | 544.11M | 415.28M | 89.80M |
| Total Liabilities | 1.22B | 1.54B | 1.58B | 1.66B | 1.65B | 1.05B |
| Stockholders Equity | 2.42B | 2.17B | 834.06M | 785.89M | 1.15B | 1.25B |
Cash Flow | ||||||
| Free Cash Flow | 137.75M | 282.43M | 174.12M | -203.26M | -543.94M | -564.45M |
| Operating Cash Flow | 411.09M | 370.25M | 211.25M | -76.65M | -303.27M | -365.78M |
| Investing Cash Flow | -543.34M | -184.86M | -137.12M | -100.28M | -153.74M | -84.13M |
| Financing Cash Flow | 548.82M | 979.86M | -92.03M | -37.82M | 587.20M | 219.44M |
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Technical Analysis
Neutral
28.70
Price Trends
57.31
Positive
52.60
Positive
48.35
Positive
Market Momentum
0.53
Positive
47.30
Neutral
44.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2315, the sentiment is Neutral. The current price of 28.7 is below the 20-day moving average (MA) of 61.44, below the 50-day MA of 57.31, and below the 200-day MA of 48.35, indicating a neutral trend. The MACD of 0.53 indicates Positive momentum. The RSI at 47.30 is Neutral, neither overbought nor oversold. The STOCH value of 44.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2315.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$197.41B | 33.16 | 10.51% | ― | 21.93% | 21.94% | |
72 Outperform | HK$62.61B | 11.04 | 128.12% | ― | 305.94% | ― | |
66 Neutral | HK$25.82B | 56.35 | 15.79% | ― | 48.04% | 166.72% | |
64 Neutral | HK$35.17B | 33.83 | 20.41% | ― | 32.63% | 8.87% | |
62 Neutral | HK$70.06B | -13.82 | -16.23% | 0.35% | 53.48% | -120.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$32.77B | -72.62 | -7.32% | ― | 34.83% | 58.94% |
* Healthcare Sector Average
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
56.10
33.10
143.91%
HK:1548
Genscript Biotech
32.36
14.98
86.19%
HK:2269
Wuxi Biologics (Cayman)
47.00
10.52
28.84%
HK:9995
RemeGen Co. Ltd. Class H
73.75
-35.65
-32.59%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
16.60
-17.14
-50.80%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
63.00
-16.50
-20.75%
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Corporate Events
Biocytogen schedules August board meeting to review interim results and dividend
Aug 17, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has scheduled a board meeting for 27 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider the potential declaration of an interim d...
Biocytogen forecasts strong interim 2026 surge driven by scale and innovation
Aug 6, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. expects a sharp improvement in its interim 2026 performance, with unaudited revenue for the first half projected between RMB936.4 million and RMB946.4 million, reflecting year-on-year growth of about ...
Biocytogen Wins First-Instance IP Ruling in Dispute Over RenNano Platform
Jun 29, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., an international biotechnology firm specializing in innovative drug research and development, positions itself as a technology-driven player in the biopharmaceutical sector. The company underscores i...
Biocytogen Shareholders Approve Remuneration Policy and Capital Mandates at EGM
Jun 25, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. reported the poll results of its second extraordinary general meeting of 2026, held in a hybrid physical and virtual format in Beijing on June 25. Shareholder participation was robust, with 286 shareh...
Biocytogen Calls 2026 EGM to Vote on Pay Framework and H-Share Buyback Mandate
Jun 4, 2026
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has called its 2026 second extraordinary general meeting for June 25, 2026, to be held both physically in Beijing and virtually online. Shareholders will consider an ordinary resolution on a new remune...
Biocytogen AGM Resolutions Passed Amid Strong Shareholder Turnout and Related-Party Abstentions
May 21, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. held its 2025 annual general meeting on May 21, 2026, in a hybrid physical and virtual format in Beijing, in compliance with PRC Company Law and its articles of association. All directors, senior mana...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.